The Trump administration’s 2025 drug policy agenda omits cannabis rescheduling, despite earlier signals of support, instead prioritizing fentanyl, border security, and addiction treatment. This omission, coupled with a...more
6/9/2025
/ Biden Administration ,
Cannabis Products ,
DEA ,
Department of Justice (DOJ) ,
Legislative Agendas ,
Marijuana ,
New Legislation ,
Opioid ,
Proposed Legislation ,
Regulatory Reform ,
Trump Administration
Since its inception, the cannabis industry has always existed alongside significant regulatory and compliance challenges. These largely stem from the fact that the manufacture, distribution and possession of marijuana remains...more
7/17/2024
/ Audits ,
Cannabis-Related Businesses (CRBs) ,
CARES Act ,
Controlled Substances Act ,
Coronavirus/COVID-19 ,
Department of Justice (DOJ) ,
False Claims Act (FCA) ,
Federal Loans ,
Investigations ,
Marijuana Related Businesses ,
Paycheck Protection Program (PPP) ,
SBA
There Has Been Little Movement in Federal Legalization. This has led to cannabis investors and companies to downgrade expectations for federal legalization and focus their strategies on state reform.
Federal lawmakers...more
7/27/2023
/ Banking Sector ,
Banks ,
Biden Administration ,
Cannabidiol (CBD) oil ,
Cannabis Products ,
Cannabis-Related Businesses (CRBs) ,
Cole Memorandum ,
Congressional Investigations & Hearings ,
DEA ,
Decriminalization of Marijuana ,
Department of Justice (DOJ) ,
Hemp ,
Hemp Related Businesses ,
Information Reports ,
Interstate Commerce ,
Marijuana ,
Marijuana Cultivation ,
Marijuana Related Businesses ,
Medical Marijuana ,
Proposed Legislation ,
Regulatory Agenda ,
State and Local Government ,
Tax Revenues ,
THC